Study S001318

Cross-over, Double-blind, Unicentric, 52 Week Trial of Liraglutide in Type 1 Diabetes.

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01787916
Acronym: LIDO
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 15
Start: 2013-04
Primary completion: 2015-04
Lead sponsor: CHU de Quebec-Universite Laval
Conditions: Type 1 Diabetes
Interventions: DRUG:Liraglutide; DRUG:Placebos
Results posted: TRUE
Individual participant data sharing: NO

Registered primary outcomes

Assessment of Changes in Glycemic Control by HbA1c. [Measure changes in HbA1c at 24 and 52 weeks from baseline]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0025536	Beyond glycaemic control: A cross-over, double-blinded, 24-week intervention with liraglutide in type 1 diabetes. Dubé MC, Diabetes, obesity & metabolism	2018	Randomized trial	PMID 28722271 DOI	cites ClinicalTrials.gov:NCT01787916; registry reference DERIVED:28722271